Healthcare Payments Player Surges as Growth Engine Accelerates

Sponsored:

Wednesday, March 25, 2026

The intersection of healthcare and financial technology continues to gain traction as providers and patients alike seek more efficient ways to manage rising medical costs. Patient affordability programs, in particular, are emerging as a critical piece of the healthcare ecosystem, helping bridge the gap between treatment access and out-of-pocket expenses while creating scalable opportunities for companies operating at the center of the payment flow.

Shares of Paysign, Inc. (NASDAQ: PAYS) are moving sharply higher Tuesday morning, after the company reported strong fourth quarter and full-year 2025 financial results following Monday’s closing bell.

Paysign, a provider of patient affordability solutions, donor compensation programs, and integrated payment processing for the life sciences industry, delivered standout growth across its core business lines. Full-year 2025 revenue rose 40.5% to $82.0 million, driven largely by rapid expansion in its patient affordability segment. The company added 55 new patient affordability programs during the year, ending 2025 with 131 active programs, which contributed to a 167.8% increase in pharma-related revenue.

That growth translated directly to the bottom line. Net income nearly doubled year-over-year to $7.55 million, while adjusted EBITDA surged 107.3% to $19.94 million. The company also exited the year with $21.07 million in unrestricted cash and no debt, providing a strong financial foundation for continued expansion.

Fourth quarter performance reinforced the trend. Revenue climbed 45.8% to $22.76 million, with pharma revenue increasing 122.4% and plasma revenue rising 16.7% compared to the prior-year period. Adjusted EBITDA for the quarter jumped 89.6% to $5.43 million, highlighting improving operating leverage as higher-margin patient affordability programs make up a larger share of the business.

Paysign’s expanding footprint in patient affordability is becoming a key driver of both growth and profitability. Claim volume increased more than 79% for the full year, underscoring strong demand for its platform as pharmaceutical companies look to improve patient access to therapies while managing reimbursement complexity.

Looking ahead, management expects continued momentum in 2026, guiding for revenue between $106.5 million and $110.5 million, representing projected growth of 30% to 35%. The company also anticipates further margin expansion, with net income expected to nearly double again as operating efficiencies scale alongside its growing program base.

With strong financial performance, a debt-free balance sheet, and a rapidly expanding presence in a critical segment of healthcare payments, Paysign is positioning itself as a company to watch as demand for patient affordability solutions continues to grow.

Sponsored: